Grant: CIHR Fellowship
Université de Montréal
$135,000.00
Generation of a novel humanized mouse model of the neuronal isoform Kif1a/25b to study hereditary sensory & autonomic neuropathy type II.
EF 2013-14
Résumé
Pain is defined as the following; an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Hence the feeling of pain reflects a state of our body in which tissue damage has been (or might be) caused. The premise of this existence is to protect us from irreparable damage to our body. But what happens when pain sensation is absent? When we become insensitive to pain? This situation usually results in disorders that exist in congenital forms in general population and the study of these disorders has been the focus of our laboratory. We are interested in a disorder named hereditary sensory neuropathy type II (HSANII) which is characterized by a loss of perception to pain, touch, and heat due to partial degeneration of peripheral sensory nerves. This condition appears within the first decade of life in the affected individuals and results in severe debilitating complications including ulcerations, infections, muscle atrophy and amputation of digits. Our laboratory reported truncating mutations in five different Canadian families of a novel gene pertaining to HSANII, namely referred as WNK1/HSN2. Additional mutations in a neuronal isoform of KIF1A/25B were found in HSANII patients of unknown etiology. Our group has also demonstrated that KIF1A/25B interacts with WNK1/HSN2 at the protein level. Hence my current research interests focuses on understanding the relationship between these two proteins in regard to HSANII. I will investigate the implication of the KIF1A/25B human mutation in HSANII development using cell based approaches and a mouse model, harbouring a KIF1A/25B human mutation. The purpose of such model is to reproduce part or all the features of HSANII to investigate the functional mechanisms of this disorder as well as to serve as a benchmark for the evaluation of future therapies. This will translate to better treatment of HSANII affected individuals in the near future.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
300890
Name
Schmouth Jean-Francois
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Generation of a novel humanized mouse model of the neuronal isoform Kif1a/25b to study hereditary sensory & autonomic neuropathy type II.
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Genetics; Hsanii; Kif1a/25b; Mouse; Neuropathy; Neuroscience; Wnk1/Hsn2
Abstract
Pain is defined as the following; an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Hence the feeling of pain reflects a state of our body in which tissue damage has been (or might be) caused. The premise of this existence is to protect us from irreparable damage to our body. But what happens when pain sensation is absent? When we become insensitive to pain? This situation usually results in disorders that exist in congenital forms in general population and the study of these disorders has been the focus of our laboratory. We are interested in a disorder named hereditary sensory neuropathy type II (HSANII) which is characterized by a loss of perception to pain, touch, and heat due to partial degeneration of peripheral sensory nerves. This condition appears within the first decade of life in the affected individuals and results in severe debilitating complications including ulcerations, infections, muscle atrophy and amputation of digits. Our laboratory reported truncating mutations in five different Canadian families of a novel gene pertaining to HSANII, namely referred as WNK1/HSN2. Additional mutations in a neuronal isoform of KIF1A/25B were found in HSANII patients of unknown etiology. Our group has also demonstrated that KIF1A/25B interacts with WNK1/HSN2 at the protein level. Hence my current research interests focuses on understanding the relationship between these two proteins in regard to HSANII. I will investigate the implication of the KIF1A/25B human mutation in HSANII development using cell based approaches and a mouse model, harbouring a KIF1A/25B human mutation. The purpose of such model is to reproduce part or all the features of HSANII to investigate the functional mechanisms of this disorder as well as to serve as a benchmark for the evaluation of future therapies. This will translate to better treatment of HSANII affected individuals in the near future.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Schmouth, Jean-Francois
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~